By Cecilia Butini
Roche Holding AG said Wednesday that the European Commission has granted conditional marketing authorization for its cancer immunotherapy drug, Lunsumio, which was studied for use in patients with relapsed or refractory follicular lymphoma.
The Swiss pharma company said the drug is a new type of treatment which is chemotherapy-free and has a fixed duration. The treatment is off-the-shelf and readily available, which means that people don't have to wait to start treatment, the company said.
The European Union's approval is based on data from a Phase 1-2 trial. Conditional approval is granted to a drug that fulfils an unmet medical need, meaning the benefit of immediate availability outweighs the risk of having less comprehensive data, Roche said.
Write to Cecilia Butini at email@example.com
(END) Dow Jones Newswires